NY-COTY
1.8.2024 14:32:27 CEST | Business Wire | Press release
Calvin Klein, Inc., part of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today launch CK One Essence, an intensified, premium take on the iconic original scent that introduces a bold addition to the CK One fragrance portfolio. Launched 30 years after the introduction of the original CK One, the new CK One Essence pays homage to the original fragrance’s olfactive DNA and celebrates its cultural legacy, reaffirming its evolution from a groundbreaking fragrance in the ‘90s to a new icon for a new era.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731704922/en/
Calvin Klein Fragrances Introduces CK One Essence (Photo: Business Wire)
[the fragrance]
This is the new intensity: Explosive. Energetic. Captivating.
To lend new emotion to the original spirit of CK One, Calvin Klein once again called upon Master Perfumer Alberto Morillas of dms-firmenich – the perfumer behind the iconic original CK One fragrance – to formulate this fresh iteration. Amplified with double the concentration of the original eau de toilette for long-lasting, powerful freshness, CK One Essence modernizes the original juice’s defiant notes to create a new olfactory symbol of timeless unity.
Top notes open the fragrance with the bright facets and fruit-forward tonalities of vibrant Italian Bergamot, responsibly sourced from a family-owned farm in Calabria, and blood orange. The juice offers an energizing and explosive profile from the first spritz.
At the heart, a curated, high-quality selection of teas, including organic green tea, invigorates and brings a modern freshness.
To ground the base, Morillas used a specific musk upcycled from the paper industry, adding a rich and sensual warmth complemented by a woody, creamy sandalwood accord.
The resulting scent is equal parts fresh, pure and sensual—an everyday uniform for a new generation.
[the campaign]
For the debut of CK One Essence, Calvin Klein partnered with visionary creative Alasdair McLellan to introduce a cast empowered by their individuality and united by the rebellious spirit at the heart of the CK One franchise. Channeling the brand’s signature black-and-white portraiture, the campaign shows the cast moving dynamically in harmony, in contrast and with total energy to the anthemic synths of New Order’s “Blue Monday.” The resulting visuals highlight the sensuality, togetherness and unity intrinsic to the heritage of CK One and celebrate a generation at one with themselves and each other.
[the packaging]
Grounded in the simplicity of the original CK One screw-top flask, both the bottle and secondary packaging were reimagined with premium, environmentally-preferred finishes. The bottle features a removable pump and a translucent metallic finish which reveals the juice inside. Its secondary metallic carton highlights the luxe nature of the new fragrance’s ingredients.
Calvin Klein CK One Essence will be available starting August 1st, 2024.
Product line-up:
1.7 FL OZ 50 ml
3.4 FL OZ 100 ml
6.7 FL OZ 200 ml (April 2025)
[the legacy]
CK One, the world’s first gender inclusive fragrance, embodied the modern minimalism at the core of the Calvin Klein brand ethos when it was introduced 30 years ago.
Launched at Tower Records in 1994, the original CK One captured the zeitgeist with a bold, defiant, anti-perfume scent that channeled music, fashion and pop culture in a bottle. The fragrance’s groundbreaking campaign forecasted a seismic shift in billboard faces, featuring street-cast misfits, moody models and real young lovers. With its pioneering attitude of universality, CK One was the first of its kind: a fragrance for everyone.
CREDITS:
Perfumer: Alberto Morillas, Master Perfumer
Campaign Photographer: Alasdair McLellan
SOCIAL MEDIA: @calvinklein
About Calvin Klein:
Calvin Klein is one of the world’s leading global fashion lifestyle brands with a history of bold, non-conformist ideals that inform everything we do. Founded in New York in 1968, the brand’s minimalist and sensual aesthetic drives our approach to product design and communication, creating a canvas that offers the possibility of limitless self-expression. The Calvin Klein brands — CK Calvin Klein, Calvin Klein, Calvin Klein Jeans, Calvin Klein Underwear, and Calvin Klein Performance — are connected by the intention and purpose of elevating everyday essentials to globally iconic status. Each of the brands has a distinct identity and position in the retail landscape, providing us the opportunity to market a range of universally appealing products to domestic and international consumers with a variety of needs. Our products are underpinned by responsible design, high-quality construction, and the elimination of all unnecessary details. We strive for unique and dimensional pieces that continuously wear well and remain relevant season after season. Global retail sales of Calvin Klein products were approximately $9 billion in 2023.
Calvin Klein continues to solidify its position as an innovator of emerging digital platforms and modern marketing campaigns. PVH acquired Calvin Klein in 2003 and continues to oversee a focused approach to growing the brand’s worldwide relevance, presence, and long term growth.
About COTY Inc.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance, and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731704922/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom